This has several important implications for manufacturers: Early launch benchmarks may understate success if they focus primarily on switching behavior rather than new-to-therapy initiation The addressable market for oral GLP-1s may be larger than previously modeled , particularly if similar barriers exist across obesity and cardiometabolic indications Pipeline assets following oral semaglutide may enter a more receptive market , where the viability of oral administration has already been established What Great Looks Like: Speed and Clinical Depth at Launch Imagine if, within weeks of launch, pharma leaders could understand the earliest signals of launch performanceincluding prescription activity, patient flow, site of care, and early access dynamicsby assessing near-real-time, large-scale claims and EMR data
But you may want to see your healthcare provider if your belching is: Ongoing and not improving with dietary or lifestyle changes Accompanied by severe nausea, vomiting, or abdominal pain Affecting your ability to eat, sleep, or socialize If you experience any of these situations, contact your healthcare provider
Research has unveiled the potential for GLP-1 receptor agonists to treat a growing range of psychiatric and neurological conditions
The clearest contraindications in the FDA labeling are a personal or family history of medullary thyroid carcinoma (MTC), the genetic condition MEN 2, and a known serious allergic reaction to the specific drug
Functional and biological insights of rCollinein-1, a recombinant serine protease from Crotalus durissus collilineatus
